Research Grade Zenocutuzumab (DHC09609)

Catalog No.

DHC09609

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

p185erbB2, HER2, NGL, Tyrosine kinase-type cell surface receptor HER2, NEU, MLN 19, Proto-oncogene Neu, MLN19, ERBB2, Proto-oncogene c-ErbB-2, CD340, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, ERBB3, HER3, Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, Receptor tyrosine-protein kinase erbB-3

Concentration

1.96 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P04626 & P21860

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Bispecific, MCLA-128, PB4188, R040517, CAS: 1969309-56-5

Clone ID

Zenocutuzumab

Zenocutuzumab Shines in PDAC, PMID: 34112697

Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade, PMID: 29763625

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose, PMID: 29728897

NRG1 fusions: Biology to therapy, PMID: 34098222

The Exciting New Field of HER2-Low Breast Cancer Treatment, PMID: 33804398

A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G 1, PMID: 28655766

Document Download

Research Grade Zenocutuzumab.pdf